Shots:

• The P-IIIb Liberty study involves assessing of Aimovig (140 mg) vs PBO @12 wks. in patients with episodic migraine (4 to 14 migraine days/month)
• P-IIIb LIBERTY study results: reduction in migrane days 50% @1EP (30% vs 14%); reduction in migrane days 75% @2EP (12% vs 4%); migrane free patients 6%; MMD (1.8 vs 0.2) reductions in the no. of days/month using acute migraine-specific medication (1.3 vs 0.5)
• Aimovig is a novel approved CGRP-targeted therapy for migrane by the US and EU including Canada- Australia- Switzerland- the UAE and Singapore

/ article | Ref: Novartis | Image:  WSJ